Latest GBS Malaysia Targets 50 Companies for AI Adoption Via Sandbox
Business News

Duopharma Biotech records strong growth in Q3 FY2024

Duopharma Biotech reports 15.4% revenue growth in Q3 FY2024, driven by strong public health sales and new government supply contracts.

Duopharma Biotech Berhad reported robust growth for Q3 FY2024, with revenue reaching RM208.73 million, pushing cumulative revenue for the year to RM620.02 million—a 15.4% increase year-on-year. The company also saw a cumulative profit before tax (PBT) increase of 11.3% and profit after tax (PAT) rise by 7.7%. This growth was largely driven by higher sales, especially in the public health sector, which balanced rising costs from the new K3 facility and increased financing expenses.

Duopharma Biotech – Growth

The company’s strategic focus on internal efficiencies and cost management continues to pay off. With the Malaysian government’s recent 10% healthcare budget increase, Duopharma sees a positive outlook for demand in public health supplies.

Additionally, two Duopharma subsidiaries received five new Letters of Offer to supply products to government facilities until December 2026, adding an estimated RM87.66 million to the order book. Duopharma also issued an interim dividend of 1.0 sen per share, totaling RM9.62 million for shareholders.

Read more Business News

Latest News Malaysia

Read More News on Business News Malaysia

Follow us on:

Read More News #latestmalaysia

BIZ NEWS CODE Business News Malaysia
Business News Malaysia Logo

Read More News on Business News Malaysia

Leave a Reply

Related stories